TriSalus Life Sciences, Inc. (TLSI) Q3 2026 Earnings Call November 10, 2026 8:30 AM EST
Company Participants
Mary Szela – CEO, President & Director
David Patience – Chief Financial Officer
Richard Marshall – Chief Medical Officer
Conference Call Participants
Frank Takkinen – Lake Street Capital Markets, LLC, Research Division
William Plovanic – Canaccord Genuity Corp., Research Division
Justin Walsh – JonesTrading Institutional Services, LLC, Research Division
Charles Wallace – H.C. Wainwright & Co, LLC, Research Division
Presentation
Operator
Thank you for standing by. My name is Kate, and I will be your conference operator today. At this time, I would like to welcome to the TriSalus Life Sciences Third Quarter 2026 Earnings Call. [Operator Instructions].
I would now like to turn the call over to Mary Szela, CEO. Please go ahead.
Unknown Attendee
Good morning, and thank you for participating in today’s call. Joining me from TriSalus are Mary Szela, President and Chief Executive Officer; David Patience, Chief Financial Officer; and Dr. Richard Marshall, Chief Medical Officer.
Earlier today, TriSalus issued a press release announcing financial results for the quarter ended September 30, 2026. A copy of the press release is available on the Investor Relations section of the company’s website. Before we begin, I’d like to remind you that management will make remarks during this call that include forward-looking statements within the meaning of federal securities laws and that these are being made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this call that relate to expectations or predictions of future events, results or performance are forward-looking statements. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied by these forward-looking statements.
Accordingly, you should not place undue reliance